Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism

Research output: Contribution to journalJournal articleResearchpeer-review

Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance.
Original languageEnglish
JournalJournal of Internal Medicine
Issue number5
Pages (from-to)406-14
Number of pages9
Publication statusPublished - Nov 2001

    Research areas

  • Adolescent, Adult, Apolipoproteins B, Body Mass Index, Diabetes Complications, Diabetes Mellitus, Fatty Acids, Nonesterified, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Insulin Resistance, Male, Mutation, Plasminogen Activator Inhibitor 1, Receptor, Insulin, Thiazoles, Thiazolidinediones, Triglycerides

ID: 92192140